Pionniers de la découverte de substances naturelles à activité thérapeutique
Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 3, Mars 2014
Pionniers de la découverte de substances naturelles à activité thérapeutique
Page(s) 319 - 328
Section Forum
DOI https://doi.org/10.1051/medsci/20143003021
Publié en ligne 31 mars 2014
  1. Cragg GM, Boyd MR, Cardellina II JH, et al. Role of plants in the National Cancer Institute drug discovery and development program. In : Kinghorn AD, Balandrin MF, eds. Human medicinal agents from plants, chapter 7. ACS Symposium Series 534, 1993.
  2. Storad CJ. Cures from the deep. Arizona State 1990 ; 22–26.
  3. Chapman AD. Numbers of living species in Australia and the world, 2nd ed. Canberra, Australia : Report for the Australian Biological Resources Study, 2009 : 84 p.
  4. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012 ; 75 : 311–335. [CrossRef] [PubMed]
  5. Abraham I, El Sayed K, Chen ZS, Guo H. Current status on marine products with reversal effect on cancer multidrug resistance. Mar Drugs 2012 ; 10 : 2312–2321. [CrossRef] [PubMed]
  6. Pettit GR, Hartwell JL, Wood HB. Arthropod antineoplastic agents. Cancer Res 1968 ; 28 : 2168–2169. [PubMed]
  7. Pettit GR, Day JF, Hartwell JL, Wood HB. Antineoplastic components of marine animals. Nature 1970 ; 227 : 962–963. [CrossRef] [PubMed]
  8. Pettit GR. Arizona State University Cancer Research Institute. In : The American Society of Pharmacognosy, 50 years of progress in natural products research 1959–2009. Madison WI : Omnipress, 2009 : 107–108.
  9. Pettit GR, Herald CL, Doubek DL, et al. Isolation and structure of bryostatin 1. J Am Chem Soc 1982 ; 104 : 6846–6848. [CrossRef]
  10. Halford B. The Bryostatins’ tale. Chem Eng News 2011 ; 89 : 10–17.
  11. Trindade-Silva AE, Lim-Fong GE, Sharp KH, Haygood MG. Bryostatins: biological context and biotechnological prospects. Curr Opin Biotech 2010 ; 21 : 834–842. [CrossRef]
  12. Keck GE, Poudel YB, Cummins TJ, et al. Total synthesis of bryostatin 1. J Am Chem Soc 2011 ; 133 : 744–747. [CrossRef] [PubMed]
  13. Haygood MG, Davidson SK. Small-subunit rRNA genes and in situ hybridization with oligonucleotides specific for the bacterial symbionts in the larvae of the bryozoan Bugula neritina and proposal of Candidatus Endobugula sertula. Appl Environ Microbiol 1997 ; 63 : 4612–4616. [PubMed]
  14. Hongpaisan J, Sun MK, Alkon DL. PKCε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer’s disease transgenic mice. J Neurosci 2011 ; 31 : 630–643. [CrossRef] [PubMed]
  15. Beans EJ, Fournogerakis D, Gauntlett C, et al. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci USA 2013 ; 110 : 11698–11703. [CrossRef]
  16. Pettit GR, Kamano Y, Herald CL, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 1987 ; 109 : 6883–6885. [CrossRef]
  17. Pettit GR, Singh SB, Hogan F, et al. Antineoplastic agents. Part 189. The absolute configuration and synthesis of natural (-)-dolastatin 10. J Am Chem Soc 1989 ; 111 : 5463–5465. [CrossRef]
  18. Pettit GR. Progress in the discovery of biosynthetic anticancer drugs. J Nat Prod 1996 ; 59 : 812–821. [CrossRef] [PubMed]
  19. Pettit GR. The Dolastatins. In : The American Society of Pharmacognosy, 50 years of progress in natural products research 1959–2009. Madison WI : Omnipress, 2009 : 224–226.
  20. Pettit GR, Herald CL, Boyd MR, et al. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem 1991 ; 34 : 3339–3340. [CrossRef] [PubMed]
  21. Hirata Y, Uemura D. Halichondrins: antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986 ; 58 : 701–710. [CrossRef]
  22. Pettit GR, Tan R, Gao F, et al. Isolation and structure of halistatin 1 from the eastern Indian Ocean marine sponge Phakellia carteri. J Org Chem 1993 ; 58 : 2538–2543. [CrossRef]
  23. Litaudon M, Hart JB, Blunt JW. Isohomohalichondrin B, a new antitumor polyether macrolide from the New Zealand deep-water sponge Lissodendoryx sp. Tetrahedron Lett 1994 ; 35 : 9435–9438. [CrossRef]
  24. Aicher TD, Buszek KR, Fang FG, et al. Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 1992 ; 114 : 3162–3164. [CrossRef]
  25. Munro HGM, Blunt JW, Dumdei EJ, et al. The discovery and development of marine compounds with pharmaceutical potential. J Biotechnol 1999 ; 70 : 15–25. [CrossRef] [PubMed]
  26. Bai R, Nguyen TL, Burnett JC, et al. Interactions of halichondrin B and eribulin with tubulin. J Chem Inf Model 2011 ; 51 : 1393–1404. [CrossRef] [PubMed]
  27. Twelves C, Cortes J, Vahdat LT, et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010 ; 10 : 160–163. [CrossRef] [PubMed]
  28. Pettit GR, Inoue M, Kamano Y, et al. Isolation and structure of the powerful cell growth inhibitor cephalostatin 1. J Am Chem Soc 1988 ; 110 : 2006–2007. [CrossRef]
  29. Fukuzawa S, Matsunaga S, Fusetani N. Isolation of 13 new ritterazines from the tunicate Ritterella tokioka and chemical transformation of ritterazine B. J Org Chem 1997 ; 62 : 4484. [CrossRef] [PubMed]
  30. LaCour TG, Guo C, Bhandaru S, et al. Interphylal product splicing: the first total syntheses of cephalostatin 1, the north hemisphere of ritterazine G, and the highly active hybrid analogue, Ritterostatin Gn1n. J Am Chem Soc 1998 ; 120 : 692–707. [CrossRef]
  31. Fortner KC, Kato D, Tanaka Y, Shair MD. Enantioselective synthesis of (+)-cephalostatin 1. J Am Chem Soc 2010 ; 132 : 275–280. [CrossRef] [PubMed]
  32. Rudy A, Lopez-Anton N, Dirsch VM, Vollmar AM. The cephalostatin way of apoptosis. J Nat Prod 2008 ; 71 : 482–486. [CrossRef] [PubMed]
  33. Pettit GR, Cichacz ZA, Gao F, et al. Isolation and structure of spongistatin 1. J Org Chem 1993 ; 58 : 1302–1304. [CrossRef]
  34. Kobayashi M, Aoki S, Sakai H, et al. Altohyrtin A, a potent anti-tumor macrolide from the Okinawan marine sponge Hyrtios altum. Tetrahedron Lett 1993 ; 34 : 2795–2798. [CrossRef]
  35. Fusetani N, Shinoda K, Matsunaga S. Bioactive marine metabolites. 48. Cinachyrolide A: a potent cytotoxic macrolide possessing two spiro ketals from marine sponge Cinachyra sp. J Am Chem Soc 1993 ; 115 : 3977–3981. [CrossRef]
  36. Bai R, Taylor GF, Cichacz ZA, et al. The spongistatins, potent cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain. Biochemistry 1995 ; 34 : 9714–9721. [CrossRef] [PubMed]
  37. Guo J, Duffy KJ, Stevens KL, et al. Total synthesis of altohyrtin A (spongistatin 1): part 1. Angewandte Chemie International Edition 1998 ; 37 : 187–190. [CrossRef]
  38. Hayward MM, Roth RM, Duffy KJ, et al. Total synthesis of altohyrtin A (spongistatin 1) : part 2. Angewandte Chemie International Edition 1998 ; 37 : 190–196. [CrossRef]
  39. Ball M, Gaunt MJ, Hook DF, et al. Total synthesis of spongistatin 1: a synthetic strategy exploiting its latent pseudo-symmetry. Angew Chem Int Ed 2005 ; 44 : 5433–5438. [CrossRef]
  40. Smith AB, III, Tomioka T, Risatti CA, et al. Gram-scale synthesis of (+)-spongistatin 1: development of an improved, scalable synthesis of the F-ring subunit, fragment union, and final elaboration. Org Lett 2008 ; 10 : 4359–4362. [CrossRef] [PubMed]
  41. Qi Y, Ma S. The medicinal potential of promising marine macrolides with anticancer activity. Chem Med Chem 2011 ; 6 : 399–409. [CrossRef]
  42. Xu Q, Huang KC, Tendyke K, et al. In vitro and in vivo anticancer activity of (+)-spongistatin 1. Anticancer Res 2011 ; 31 : 2773–2779. [PubMed]
  43. Pettit GR, Cragg GM, Herald DL, et al. Isolation, structure of combretastatin. Can J Chem 1982 ; 60 : 1374. [CrossRef]
  44. Annapurna GS, Deshpande VH. Synthesis of (±) combretastatin. Synth Commun 1983 ; 13 : 1075–1082. [CrossRef]
  45. Pettit GR, Singh SB, Cragg GM. Antineoplastic agents. 113. Synthesis of natural (-)-combretastatin. J Org Chem 1985 ; 50 : 3404–3406. [CrossRef]
  46. Pettit GR, Temple CJR, Nnarayanan VL, et al. Antineoplastic agent 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 1995 ; 10 : 299–309. [PubMed]
  47. Pettit GR, Pinney KG. The Combretastatins. In : The American Society of Pharmacognosy, 50 years of progress in natural products research 1959–2009. Madison WI : Omnipress, 2009 : 217–219.
  48. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009 ; 18 : 189–197. [CrossRef] [PubMed]
  49. Ibrahim MA, Do DV, Sepah YJ, et al. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety, efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol 2013 ; 14 : 7. [CrossRef] [PubMed]
  50. Pettit GR, Gaddamidi V, Cragg GM, et al. Isolation and structure of pancratistatin. J Chem Soc Chem Commun 1984 ; 1693–1694. [CrossRef]
  51. Ceriotti G. Narciclasine: an antimitotic substance from Narcissus bulbs. Nature 1967 ; 213 : 595–596. [CrossRef] [PubMed]
  52. Danishefsky SJ, Lee JY. Total synthesis of (+)-Pancratistatin. J Am Chem Soc 1989 ; 111 : 4829–4837. [CrossRef]
  53. McLachlan A, Kekre N, McNulty J, Pandey S. Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis. Apoptosis 2005 ; 10 : 619–630. [CrossRef] [PubMed]
  54. Griffin C, Hamm C, McNulty J, Pandey S., Pancratistatin induces apoptosis in clinical leukemia samples with minimal effect on non-cancerous peripheral blood mononuclear cells. Cancer Cell Int 2010 ; 10 : 6. [CrossRef] [PubMed]
  55. Da Silva PPJ, Meijer L. Recherche de substances naturelles à activité thérapeutique. Pierre Potier (1934–2006). Med Sci (Paris) 2012 ; 28 : 534–542. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.